Navigation Links
Study validates means to measure possible leukemia marker

COLUMBUS, Ohio A study led by cancer researchers at The Ohio State University has validated a method for reliably measuring variations in certain proteins that may make good biomarkers in chronic leukemia patients.

The study shows that liquid chromatography-mass spectrometry (LC-MS) can measure variations in histones, which are spool-like proteins that help support and store DNA. The technology accurately detected differences in the composition of histones in chronic lymphocytic leukemia (CLL) cells compared with their healthy counterparts, immune cells called B lymphocytes.

These variations are a promising molecular biomarker that might improve the diagnosis and gauge response to therapy in CLL patients.

The findings are published online in a recent issue of the journal Proteomics.

"Now that we have validated the technique, we can apply it to study histones as biomarkers that clinicians can use to make decisions about diagnosis and treatment," says principal investigator Michael A. Freitas, a researcher in the Ohio State University Comprehensive Cancer Center's Experimental Therapeutics Program.

Freitas and his colleagues used LC-MS to analyze variations in histones in 40 CLL patients and four healthy patients. It showed significant changes in the relative abundance of histone H2A variants in CLL cells compared with healthy B cells and suggested a correlation between these changes and the severity of CLL.

To verify the accuracy of their measurements, the investigators tested the technology against common sources of error that can arise in clinical testing laboratories. These included analyzing samples prepared in different ways and by different people, and using different instruments. They also re-analyzed samples that were nearly two years old.

"All of these can be huge problems in biomarker analysis," Freitas says. "The danger is that patients can end up being separated into groups based on changes in how the analysis is done rather than on actual changes in the biomarker.

"We still need to be concerned about experimental bias," he says, "but this study demonstrates that we can detect real biological differences in histones in CLL cells, as opposed to methodological differences."


Contact: Darrell E. Ward
Ohio State University Medical Center

Related biology news :

1. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
2. A study by the MUHC and McGill University opens a new door to understanding cancer
3. Study begins to reveal clues to the cause and progression of sepsis
4. Clones on task serve greater good, evolutionary study shows
5. New study warns limited carbon market puts 20 percent of tropical forest at risk
6. New study examines how rearing environment can alter navigation
7. Study links cat disease to flame retardants in furniture and to pet food
8. New continent and species discovered in Atlantic study
9. Study shows link between alcohol consumption and hiv disease progression
10. Feeling hot, hot, hot: New study suggests ways to control fever-induced seizures
11. Study finds environmental tests help predict hospital-acquired Legionnaires disease risk
Post Your Comments:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... ) The integration will ... to access and transact across channels. Using this ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... focused on quality, regulatory and technical consulting, provides a free webinar ... presented on July 13, 2016 at 12pm CT at no charge. , Incomplete ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
Breaking Biology Technology: